Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals

NCT00001462 is registered in ClinicalTrials.gov with National Heart, Lung, and Blood Institute (NHLBI) as lead sponsor.

NCT NCT00001462
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00001462 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Characterization of the Pathobiology of Early Lung Destruction in Alpha 1-Antitrypsin Deficient Individuals
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Phase
Observational
Overall status
Completed
Start date
May 31, 1995
Completion date
April 30, 2000
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alpha 1-antitrypsin deficiency, emphysema, lung diseases, obstructive